These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 523449)

  • 1. [Our experience with the treatment of multiple myeloma and its complications].
    Abdulkadyrov KM; Ushakova EA
    Probl Gematol Pereliv Krovi; 1979 Dec; 24(12):35-40. PubMed ID: 523449
    [No Abstract]   [Full Text] [Related]  

  • 2. [Our experience with chemotherapy in the treatment of orofacial cancers].
    Crepy C
    Rev Stomatol Chir Maxillofac; 1974; 75(1):166-9. PubMed ID: 4531682
    [No Abstract]   [Full Text] [Related]  

  • 3. [Treatment of myeloma disease].
    Verevkin IN
    Med Sestra; 1981 Nov; 40(11):5-7. PubMed ID: 6915349
    [No Abstract]   [Full Text] [Related]  

  • 4. The management of multiple myeloma.
    Luikart S; Weininger RB
    Conn Med; 1980 Sep; 44(9):553-6. PubMed ID: 7408479
    [No Abstract]   [Full Text] [Related]  

  • 5. [Clinical study on chemotherapy for multiple myeloma. Part III: The disappearance of M-protein in multiple myeloma].
    Adachi T; Hasegawa M; Asano K; Sezaki T; Ishii H; Takahashi I; Kimura I
    Rinsho Ketsueki; 1983 Apr; 24(4):440-7. PubMed ID: 6887544
    [No Abstract]   [Full Text] [Related]  

  • 6. Effectiveness of two-stage treatment of multiple myeloma with melphalan and with melphalan in combination with cyclophosphamide, carmustine, vincristine and prednisone.
    Snigurowicz J; Kraj M; Rostkowska J; Maj S; Mariańska B; Mendek E; Roszkowski S; Kilian Z; Kołakowski L
    Arch Immunol Ther Exp (Warsz); 1981; 29(2):145-53. PubMed ID: 7030265
    [No Abstract]   [Full Text] [Related]  

  • 7. Polychemotherapy (COMP) treatment in myeloma patients. A preliminary report.
    Izzi T; Polchi P; Moretti L; Lucarelli G
    Haematologica; 1983; 68(3):381-91. PubMed ID: 6411532
    [No Abstract]   [Full Text] [Related]  

  • 8. [Renal insufficiency and myeloma: therapeutic success in relation to reduction of tumor mass].
    Bondía Román A; San Miguel J; Guervos CS; Batlle F; Tabernero Romo JM; López-Borrasca A
    Rev Clin Esp; 1982 Feb; 164(3):191-2. PubMed ID: 7089337
    [No Abstract]   [Full Text] [Related]  

  • 9. Should prophylactic granulocyte-colony stimulating factor be used in multiple myeloma patients developing neutropenia under lenalidomide-based therapy?
    Mateos MV; García-Sanz R; Colado E; Olazábal J; San-Miguel J
    Br J Haematol; 2008 Feb; 140(3):324-6. PubMed ID: 18067473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thalidomide maintenance following high-dose therapy in multiple myeloma: a UK myeloma forum phase 2 study.
    Feyler S; Rawstron A; Jackson G; Snowden JA; Cocks K; Johnson RJ
    Br J Haematol; 2007 Nov; 139(3):429-33. PubMed ID: 17910633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does low-dose aspirin have antineoplastic effects in multiple myeloma?
    Baz R; Hussein MA
    Br J Haematol; 2006 Aug; 134(3):349-50. PubMed ID: 16848779
    [No Abstract]   [Full Text] [Related]  

  • 12. Combination CCNU and bleomycin therapy for squamous cell carcinoma.
    Lindell TD; Moseley HS; Fletcher WS
    Am Surg; 1974 May; 40(5):281-9. PubMed ID: 4132376
    [No Abstract]   [Full Text] [Related]  

  • 13. Rapid complete remission in multiple myeloma with bortezomib/thalidomide/dexamethasone combination therapy following development of tumor lysis syndrome.
    Chim CS
    Cancer Chemother Pharmacol; 2008 Jun; 62(1):181-2. PubMed ID: 17846773
    [No Abstract]   [Full Text] [Related]  

  • 14. [Trial of combination chemotherapy for multiple myeloma and macroglobulinemia--VENAP therapy (author's transl)].
    Furukawa K; Fujiwara Y; Nakaide Y; Tanaka M; Tanaka M; Hirota Y
    Rinsho Ketsueki; 1980 Nov; 21(11):1683-91. PubMed ID: 6782278
    [No Abstract]   [Full Text] [Related]  

  • 15. [Effective combination therapy of bortezomib and dexamethasone for two patients with refractory multiple myeloma].
    Ikeda H; Hayashi T; Nojima M; Yasui H; Ikeda Y; Ishida T; Adachi M; Imai K
    Rinsho Ketsueki; 2005 Apr; 46(4):269-73. PubMed ID: 16444959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment of chronic myeloid and lymphoid leukemias, and of multiple myeloma (author's transl)].
    Stryckmans P; Malarmé M
    Rev Med Brux; 1980 May; 1(5):307-10. PubMed ID: 6936745
    [No Abstract]   [Full Text] [Related]  

  • 17. [Current status of treatment for multiple myeloma].
    Tsuchiya J
    Gan To Kagaku Ryoho; 1982 Nov; 9(11):1911-20. PubMed ID: 7184381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy and safety of bortezomib (velcade) in the treatment of relapsed multiple mye.
    Warzocha K; Kraj M; Pogłód R; Sokołowska U
    Acta Pol Pharm; 2006; 63(5):452-5. PubMed ID: 17357614
    [No Abstract]   [Full Text] [Related]  

  • 19. Myeloma.
    Malpas JS
    Br J Hosp Med; 1977 Nov; 18(5):478, 481-4, 487. PubMed ID: 597659
    [No Abstract]   [Full Text] [Related]  

  • 20. Renal safety of 1-hour pamidronate infusion for breast cancer and multiple myeloma patients: comparison between clinical trials and population-based database.
    de Lemos ML; Taylor SC; Barnett JB; Hu F; Levin A; Moravan V; O'Reilly SE
    J Oncol Pharm Pract; 2006 Dec; 12(4):193-9. PubMed ID: 17156591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.